HIV-associated facial lipoatrophy - Review of current therapy options

European Journal of Medical Research

Volumn 13, Issue 3, 2008, Pages 93-99

  Bechara, F G ^a   Sand, M ^a   Potthoff, A ^a   Altmeyer, P ^a   Brockmeyer, N H ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Facial lipoatrophy lipodystrophy syndrome; HIV

Indexed keywords

ACRYLIC ACID METHYL ESTER; ANABOLIC AGENT; ANTIDIABETIC AGENT; ANTIRETROVIRUS AGENT; COLLAGEN IMPLANT; FILLER; HUMAN GROWTH HORMONE; HYALURONIC ACID; HYDROXYAPATITE; METFORMIN; POLYACRYLAMIDE GEL; POLYAMIDE; POLYLACTIC ACID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SILICONE; STAVUDINE;

AUTOTRANSPLANTATION; BODY FAT DISTRIBUTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECCHYMOSIS; ERYTHEMA; ESTHETIC SURGERY; FACIAL LIPOATROPHY; FOREIGN BODY REACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; LIPOATROPHY; LIVER TOXICITY; POLITEF IMPLANT; REVIEW; RHYTIDOPLASTY; SIDE EFFECT; SKIN EDEMA; SKIN PAIN; SKIN PRURITUS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FACE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY;

EID: 42449125621     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Wanke CA, Falutz JM, Shevitz A (2002) Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis; 34: 248-59.
2. Dieterich DT (2003) Long-term complications of nucleoside reverse transcriptase inhibitor therapy. AIDS Read; 13: 176-84.
3. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS; 12: F51-8.
4. Carr A, Cooper DA (2000) Adverse effects of antiretroviral therapy. Lancet; 356: 1423-30.
5. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet; 353: 2093-9.
6. Chastain MA, Chastain JB, Coleman WP (2001) HIV lipodystrophy: review of the syndrome and report of a case treated with liposuction. Dermatol Surg; 27: 497-500.
7. Martinez E, Garcia-Viejo MA, Blanch J, Gatell JM (2001) Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Saf; 24: 157-66.
8. Graber AL (2001) Syndrome of lipodystrophy, hyperlipidemia, insulin resistance, and diabetes in treated patients with human immunodeficiency virus infection. Endocr Pract; 7: 430-7.
9. Jan V, Cervera P, Maachi M (2004) Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther; 9: 555-64.
10. McComsey G, Walker UA (2004) Role of mitochondria in HIV lipoatrophy: Insight into pathogenesis and potential therapies. Mitochondrion; 4: 111-118.
11. Burgoyne R, Collins E, Wagner C, Abbey S, Halman M, Nur M, Walmsley S, (2005) The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res; 14: 981-90.
12. Collins E, Wagner C, Walmsley S (2000) Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read; 10: 546-50.
13. James J, Carruthers A, Carruthers J (2002) HIV-associated facial lipoatrophy. Dermatol Surg; 28: 979-86.
14. Drechsler H, Powderly WG (2002) Switching effective antiretroviral therapy: a review. Clin Infect Dis; 35: 1219-30.
15. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, Cooper DA (2002) Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA; 288: 207-15.
16. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, Hoy J, Workman C, Doong N. Freund J, Cooper DA; Mitochondrial Toxicity Study Group (2004) Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS; 18: 1029-36.
17. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, Cooper DA; Rosey investigators (2004) No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet; 363: 429-38.
18. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S (2000) Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA; 284: 472-7.
19. Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, Jarvinen A, Ristola M, Yki-Jarvinen H (2003). Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir Ther; 8: 199-207.
20. van Wijk JP, de Koning EJ, Cabezas MC, op't Roodt J, Joven J, Rabelink TJ, Hoepelman AI (2005) Comparison of rosightazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med; 143: 337-46.
21. Burgess E, Wanke C (2005) Use of recombinant human growth hormone in HIV-associated lipodystrophy. Curr Opin Infect Dis; 18: 17-24.
22. Honda M, Yogi A, Ishizuka N, Genka I, Gatanaga H, Teruya K, Tachikawa N, Kikuchi Y, Oka S (2007) Effectiveness of subcutaneous growth hormone in HIV-1 patients with moderate to severe facial lipoatrophy. Intern Med; 46: 359-62.
23. Gold J, Batterham MJ, Rekers H, Harms MK, Geurts TB, Helmyr PM, Silva de Mendonca J, Falleiros Carvalho LH, Panos G, Pinchera A, Aiuti F, Lee C, Horban A, Gatell J, Phanuphak P, Prasithsirikul W, Gazzard B, Bloch M, Danner SA; E-1696 Study Investigators (2006) Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting. HIV Med; 7: 146-55.
24. Narins R, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S (2003) A randomized, double blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the corrections of nasolabial folds. Dermatol Surg; 29: 588-595.
25. Cheng NX, Xu SL, Deng H, Ding XB, Zhang XM, Wu DH, Zhong H, Sun ZH (2006) Migration of implants: a problem with injectable polyacrylamide gel in aesthetic plastic surgery. Aesthetic Plast Surg; 30: 215-25.
26. Jones DH, Carruthers A, Orentreich D, Brody HJ, Lai MY, Azen S, Van Dyke GS (2004) Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial. Dermatol Surg; 30: 1279-86.
27. Alster TS, West TB (2000) Human-derived and new synthetic injectable materials for soft-tissue augmentation: current status and role in cosmetic surgery. Plast Reconstr Surg; 105: 2515-2524.
28. Jones D (2005) HIV facial lipoatrophy: causes and treatment options. Dermatol Surg; 31: 1519-1529.
29. Tsao S. Injectable Alloderm. for augmentation of HIV-positive protease inhibitor-induced facial lipoatrophy. Presented at the ASDS-ACMMSCO Combined Annual Meeting; 2002 Oct. 31.-Nov. 3.; Chicago, IL.
30. Naoum C (2006) Cheek and facial contour augmentation with subcutaneous application of hyaluronic acid in HIV-positive patients. Cosmetic Medicine; 4: 170-173.
31. Funk E, Bressler FJ, Brissett AE (2006) Contemporary surgical management of HIV-associated facial lipoatrophy. Otolaryngol Head Neck Surg; 134: 1015-1022.
32. Gooderham M, Solish N (2005) Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy. Dermatol Surg; 31: 104-8.
33. Burres S (1999) Preserved particulate fascia lata for injection: a new alternative. Dermatol. Surg; 25: 790-794.
34. Burres S (2001). Soft-tissue augmentation with Fascian. Clin Plast Surg; 28: 101-10.
35. Talmor M, Hoffman LA, LaTrenta GS (2002) Facial atrophy in HIV-related fat redistribution syndrome: anatomic evaluation and surgical reconstruction. Ann Plast Surg; 49: 11-7.
36. Tien PC, Grunfeld C (2004) What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis; 17: 27-32.
37. Serra-Renom JM, Fontdevila J (2004) Treatment of facial fat atrophy related to treatment with protease inhibitors by autologous fat injection in patients with human immunodeficiency virus infection. Plast Reconstr Surg; 114: 551-5.
38. Levan P, Nguyen TH, Lallemand F, Mazetier L, Mimoun M, Rozenbaum W, Girard PM (2002). Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS; 16: 1985-7.
39. Cheng JT, Perkins SW, Hamilton MM (2001) Collagen and injectable fillers. Otolaryngol Clin North Am; 9: 405-411.
40. Guaraldi G, De Fazio D, Orlando G, Murd R, Wu A, Guaraldi P, Esposito R (2005) Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. Clin Infect Dis; 40: 13-5.
41. Strauch B, Baum T, Robbins N (2004) Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area. Plast Reconstr Surg; 113: 363-70.
42. Barton SE, Engelhard P, Conant M (2006) Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies. Int J STD AIDS; 17: 429-35.
43. Moyle GJ, Lysakova L, Brown S (2004) A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med; 5: 82-7.
44. Humble G, Mest D (2004) Soft tissue augmentation using sculptra. Facial Plast Surg; 20: 157-63.
45. Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H (2003) Polylactic acid implants (New Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS; 17: 2471-7.
46. Comite SL, Liu JF, Balasubramanian S (2004) Treatment of HIV associated facial lipoatrophy with Radiance FN (Radiesse). Dermatol Online J; 10: 2.
47. Sankar V, McGuff HS (2007). Foreign body reaction to calcium hydroxylapatite after lip augmentation. J Am Dent Assoc; 138: 1093-6.
48. Silvers S, Eviatar JA, Evachez MI, Pappas AL (2006) Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg; 118: 34-45.
49. Orentreich D, Leone AS (2004) A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone. Dermatol Surg; 30: 548-51.
50. Narins RS, Beer K (2006) Liquid injectable silicone: a review of its history, immunology, technical considerations, complications, and potential. Plast Reconstr Surg; 118: 77-84.
51. Lemperle G, Romano JJ, Busso M (2003) Soft tissue augmemtation with artecoll: 10-year history, indications, techniques, and complications. Dermatol Surg; 29: 573-87.
52. Lemperle G, Morhenn V, Charrier U (2003) Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg; 27: 354-66.
53. Mole B (2006) Lasting treatment of facial HIV and non HIV lipoatrophies through the use of SAM GoreTex malar implants and polyacrylamide hydrogel filler Eutrophill. About 90 consecutive cases. Ann Chir Plast Esthet; 51: 129-41.
54. Guaraldi G, Orlando G, De Fazio D, De Lorenzi I, Rottino A, De Santis G, Pedone A, Spaggiari A, Baccarani A, Borghi V, Esposito R (2005) Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. Antivir Ther; 10: 753-9.
55. Protopapa C, Sito G, Caporale D, Cammarota N (2003) Bio-Alcamid in drug-induced lipodystrophy. J Cosmet Laser Ther; 5: 226-30.
56. Ramon Y, Fodor L, Ullmann Y (2007) Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy. Dermatology; 214: 151-4.
57. Karim RB, Hage JJ, van Rozelaar L, Lange CA, Raaijmakers J. Complications of polyalkylimide 4% injections (Bio-Alcamid): a report of 18 cases (2006). J Plast Reconstr Aesthet Surg. 59: 1409-14.
58. Catanese J 3rd, Cooke D, Maas C, Pruitt L (1999) Mechanical properties of medical grade expanded polytetra-fluoroethylene: the effects of internodal distance, density, and displacement rate. J Biomed Mater Res; 48: 187-92.
59. Mori A, Lo Russo G, Agostini T, Pattarino J, Vichi F, Dini M (2006). Treatment of human immunodeficiency virus-associated facial lipoatrophy with lipofilling and submalar silicone implants. J Plast Reconstr Aesthet Surg; 59: 1209-1216.
60. Binder WJ, Bloom DC (2004) The use of custom-designed midfacial and submalar implants in the treatment of facial wasting syndrome. Arch Facial Plast Surg; 6: 394-7.